Immutep Ltd has released a press release.
Appendix 4E & 2020 Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Recruitment of stage 1 of part B in TACTI-002 study complete
- Immutep granted US patent for eftilagimod alpha
- US patent granted for IMP701 antibody
- Immutep Completes Recruitment for Part A of TACTI-002 trial
- Immutep receives A$1,437,826 R&D Tax Incentive
Later from Immutep
- IMM & Monash Uni receive funding grant for LAG-3 Research
- Immutep reports improving results from INSIGHT-004 trial
- Immutep granted European patent for IMP761
- COVID-19 phase 2 investigator initiated trial commences
- 2020 AGM Presentation
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep